Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Revenue: 2023-2025

Historic Revenue for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to $1.6 million.

  • Entrada Therapeutics' Revenue fell 91.75% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.5 million, marking a year-over-year decrease of 71.42%. This contributed to the annual value of $210.8 million for FY2024, which is 63.38% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Revenue is $1.6 million, which was down 17.23% from $1.9 million recorded in Q2 2025.
  • Entrada Therapeutics' Revenue's 5-year high stood at $94.7 million during Q2 2024, with a 5-year trough of $1.6 million in Q3 2025.
  • Moreover, its 3-year median value for Revenue was $25.3 million (2023), whereas its average is $33.1 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Revenue surged by 421.16% in 2024, and later crashed by 97.94% in 2025.
  • Over the past 3 years, Entrada Therapeutics' Revenue (Quarterly) stood at $41.8 million in 2023, then declined by 10.63% to $37.4 million in 2024, then plummeted by 91.75% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.9 million for Q2 2025, and $20.6 million during Q1 2025.